While Q1 benefited from COVID-19-driven medicine-cabinet/cupboard stocking up, particularly in the Pharmaceuticals and Consumer Healthcare segments, the momentum should fade away in Q2 20. Lower demand for Shingrix, due to lockdowns, is also concerning. However, the HIV franchisee is quite resilient and, combined with the label extension of Zejula, should ensure growth continuing in H2. Adjuvant technology for the mass production of COVID-19 vaccines would allow GSK to capitalise on COVID-rel
01 May 2020
After a robust Q1, Q2 could be a COVID-19 casualty
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
After a robust Q1, Q2 could be a COVID-19 casualty
GSK plc (GSK:LON) | 1,638 -245.8 (-0.9%) | Mkt Cap: 67,914m
- Published:
01 May 2020 -
Author:
Rishabh Kochar -
Pages:
4
While Q1 benefited from COVID-19-driven medicine-cabinet/cupboard stocking up, particularly in the Pharmaceuticals and Consumer Healthcare segments, the momentum should fade away in Q2 20. Lower demand for Shingrix, due to lockdowns, is also concerning. However, the HIV franchisee is quite resilient and, combined with the label extension of Zejula, should ensure growth continuing in H2. Adjuvant technology for the mass production of COVID-19 vaccines would allow GSK to capitalise on COVID-rel